Last Updated:
10 Mar 2026, 03:27:01 PM (IST)
Lasa Supergenerics Limited
NSE: LASA BSE: LASA
NSE
7.86
0.12 (1.55%)
Prev Close
7.74
Open Price
7.95
Volume
31,165
Today Low / High
7.52 / 8.15
52 WK Low / High
7.18 / 23.33
Range
7 - 8
BSE
7.95
-0.04 (-0.50%)
Prev Close
7.99
Open Price
7.51
Volume
18,369
Today Low / High
7.4 / 8.75
52 WK Low / High
7.13 / 23
Range
8 - 8
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 7.86 (target range: 7 - 8), reflecting a change of 0.12 (1.55039%). On the BSE, it is listed at 7.95 (target range: 8 - 8), showing a change of -0.04 (-0.50063%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Lasa Supergenerics Limited Graph
Lasa Supergenerics Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lasa Supergenerics Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 7.86, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 7.95 | 8.03 | 7.23 - 8.83 |
| 8.11 | 6.49 - 9.73 | ||
| 8.19 | 5.73 - 10.65 | ||
| Bearish Scenario | 7.95 | 7.87 | 7.08 - 8.66 |
| 7.79 | 6.23 - 9.35 | ||
| 7.71 | 5.40 - 10.02 |
Overview of Lasa Supergenerics Limited
ISIN
INE670X01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
68,174
Market Cap
389,787,639
Last Dividend
0
Official Website
IPO Date
2017-09-21
DCF Diff
6.08
DCF
2
Financial Ratios Every Investor Needs
Stock Dividend of LASA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-16 | September 16, 22 | 0.25 | 0.25 | 2022-09-19 | 2022-10-26 | |
| 2021-09-15 | September 15, 21 | 0.25 | 0.25 | 2021-09-16 | 2021-10-24 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 142.45 Cr | 106.19 Cr | 36.26 Cr | 0.2546 | 0.17 Cr | 0.00 Cr | -6.03 Cr | -14.76 Cr | -2.95 | -4.39 Cr | -0.1036 |
| 2024-03-31 | 104.34 Cr | 75.22 Cr | 28.70 Cr | 0.2750 | 0.13 Cr | 3.22 Cr | -8.43 Cr | -21.73 Cr | -4.34 | -6.47 Cr | -0.2083 |
| 2023-03-31 | 129.57 Cr | 140.76 Cr | -11.19 Cr | -0.0863 | 0.10 Cr | 3.57 Cr | -18.10 Cr | -38.62 Cr | -7.71 | -24.69 Cr | -0.2981 |
| 2022-03-31 | 137.13 Cr | 94.34 Cr | 42.78 Cr | 0.3120 | 0.20 Cr | 5.10 Cr | 2.33 Cr | -5.33 Cr | -1.06 | 8.41 Cr | -0.0389 |
| 2021-03-31 | 202.38 Cr | 113.69 Cr | 88.69 Cr | 0.4382 | 0.37 Cr | 4.00 Cr | 31.44 Cr | 22.78 Cr | 5.60 | 46.99 Cr | 0.1125 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.28 Cr | 101.53 Cr | 17.82 Cr | 83.7133 Cr | 2.13 Cr | 1.85 Cr | 24.50 Cr | 48.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 17.1545 Cr |
| 2024-03-31 | 0.61 Cr | 150.87 Cr | 54.19 Cr | 96.6762 Cr | 22.08 Cr | 21.47 Cr | 19.04 Cr | 86.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 48.8705 Cr |
| 2023-03-31 | 0.80 Cr | 163.86 Cr | 45.57 Cr | 118.2860 Cr | 21.77 Cr | 20.97 Cr | 13.90 Cr | 92.78 Cr | 0.00 Cr | 0.00 Cr | 0.39 Cr | 42.7279 Cr |
| 2022-03-31 | 11.07 Cr | 209.17 Cr | 51.29 Cr | 157.8829 Cr | 20.17 Cr | 9.11 Cr | 11.50 Cr | 125.09 Cr | 0.18 Cr | 0.00 Cr | 0.38 Cr | 44.7497 Cr |
| 2021-03-31 | 3.84 Cr | 207.86 Cr | 48.94 Cr | 158.9171 Cr | 19.46 Cr | 15.62 Cr | 17.26 Cr | 137.51 Cr | 0.04 Cr | 0.00 Cr | 0.02 Cr | 40.5354 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -2.8237 Cr | 8.1520 Cr | -5.6616 Cr | -2.8237 Cr | -0.3333 Cr | 0.2753 Cr | 0.0000 Cr | -19.3831 Cr | -5.2526 Cr | 0.0000 Cr | -5.4537 Cr |
| 2024-03-31 | 2.1387 Cr | -0.3978 Cr | -1.9319 Cr | 2.1387 Cr | -0.1909 Cr | 0.6086 Cr | 0.0000 Cr | -21.7306 Cr | 0.3064 Cr | 0.0000 Cr | -5.1404 Cr |
| 2023-03-31 | -17.3004 Cr | 11.1949 Cr | -4.1606 Cr | -17.3004 Cr | -10.2661 Cr | 0.7995 Cr | 0.0000 Cr | -22.3685 Cr | 0.0000 Cr | 0.0000 Cr | -2.4053 Cr |
| 2022-03-31 | 9.2116 Cr | -2.9119 Cr | -0.0403 Cr | 9.2116 Cr | 6.2594 Cr | 11.0656 Cr | 0.0000 Cr | 1.6506 Cr | 0.0000 Cr | 0.0000 Cr | 5.7609 Cr |
| 2021-03-31 | 41.3103 Cr | -3.5967 Cr | -36.4433 Cr | 34.7237 Cr | 1.2703 Cr | 3.8387 Cr | -6.5866 Cr | 29.4914 Cr | -34.4802 Cr | 0.0000 Cr | 9.0462 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 2.20 Cr | 3.99 Cr | -1.79 Cr | -0.8155 | -2.32 Cr | -2.55 Cr | -0.51 | -0.75 Cr | -1.1616 |
| 2025-09-30 | 3.06 Cr | 5.53 Cr | -2.47 Cr | -0.8071 | -5.57 Cr | -6.25 Cr | 1.25 | -3.99 Cr | -2.0424 |
| 2025-06-30 | 20.01 Cr | 15.69 Cr | 4.32 Cr | 0.2160 | -2.07 Cr | -21.12 Cr | -4.22 | -20.94 Cr | -1.0553 |
| 2025-03-31 | 39.14 Cr | 28.33 Cr | 10.81 Cr | 0.2763 | -1.01 Cr | -14.29 Cr | -2.86 | -7.77 Cr | -0.3652 |
| 2024-12-31 | 33.08 Cr | 24.51 Cr | 8.57 Cr | 0.2589 | -2.01 Cr | 5.49 Cr | 1.10 | 0.79 Cr | 0.1661 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.29 Cr | 0.41 Cr | 0.70 Cr | 1.64 Cr | 4.18 Cr | 12.38 Cr | 40.16 Cr | 71.60 Cr | 15.26 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.79 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -83.71 Cr |
| 2025-03-31 | 0.28 Cr | 0.52 Cr | 0.79 Cr | 1.54 Cr | 24.50 Cr | 32.51 Cr | 48.34 Cr | 101.53 Cr | 17.82 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.13 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -90.72 Cr |
| 2024-09-30 | 0.73 Cr | 0.40 Cr | 1.13 Cr | 3.74 Cr | 20.24 Cr | 39.33 Cr | 83.73 Cr | 147.33 Cr | 56.61 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -21.12 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -14.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 5.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -3.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -2.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Chairman & MD
Omkar Pravin Herlekar
Gender: Not Specified
Year Born: 1981
Senior Accounts Officer
Anil Fargade
Gender: male
Year Born:
Whole Time Director
Prathamesh Chalke
Gender: male
Year Born:
Manager of HR & Admin
Sunil Sitale
Gender: male
Year Born:
Chief Financial Officer
Varsha Pravin Joshi
Gender: female
Year Born:
FAQs about Lasa Supergenerics Limited
Who is the CEO of the company?
The CEO is Omkar Pravin Herlekar.
What is the current market price of the stock?
The current price is ₹7.78.
What is the 52-week price range?
The range is ₹7.36-25.15.
What is the market capitalization of the company?
The market capitalization is ₹38.98 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -0.88.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lasa Supergenerics Limited (ISIN: INE670X01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹38.98 crores and an average daily volume of 68,174 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.